Is it true that pomegranate juice may slow the growth of prostate cancer?
Some research suggests that drinking pomegranate juice may slow the progression of prostate cancer Read the article.
Questions to Ask Before Participating in a Prostate Cancer Clinical Trial
Several key questions that a participant will want answered before enrolling in a clinical trial are listed here. It is important that people learn as much as possible prior to entering a trial, and to thoroughly discuss the study with a doctor and with the study team. Read the article.
Extended lymph node dissection in robotic radical prostatectomy
Studies have shown that radical prostatectomy can improve progression-free and overall survival in patients with lymph node-positive prostate cancer. While this finding requires further validation, it does allow urologists to question the former treatment paradigm of aborting surgery when lymph node invasion from prostate cancer occurred, especially in patients with limited lymph node tumor infiltration. Studies show that intermediate- and high-risk patients should undergo extended pelvic lymph node dissection up to the common iliac arteries in order to improve nodal staging. Read the article.
Revolutionary new drug could help sex lives of thousands of prostate cancer suffers
A revolutionary new light activated drug will spare thousands of men with prostate cancer from the misery of ruined sex lives. The treatment involves injecting a light sensitive drug into the blood stream. When infra red light is shone on the prostate, it destroys the blood vessels feeding the tumour, killing it. Read the article.
Study Suggests Chemotherapy After Radical Prostatectomy May Benefit Men Who Are At High Risk for Relapse
Not all men with prostate cancer benefit from adjuvant chemotherapy after radical prostatectomy; however, African American men and men with a higher tumor stage may, according to a new U.S. Department of Veterans Affairs (VA) study. Read the article.
Landmark PSA Screening Trial Results Challenged
Recommendations against routine PSA screening from the US Preventive Services Task Force (USPSTF) are based largely on a landmark trial showing that such screening does not decrease the risk of death from prostate cancer (PCa), but this conclusion may be invalid. Read the article.
Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy
A study evaluated experience with salvage brachytherapy after discovery of biochemical recurrence after a prior brachytherapy procedure. Twenty-one patients treated by brachytherapy within University of Kentucky or from outside centers developed biochemical failure and had no evidence of metastases. Conclusions. Salvage brachytherapy after primary brachytherapy is possible; however, the side-effect profile after the second brachytherapy procedure was higher than after the first brachytherapy procedure. Read the article.
SBRT for prostate cancer treatment offers higher cure rate than many traditional approaches
A five-year study shows that Stereotactic Body Radiation Therapy (SBRT) to treat prostate cancer offers a higher cure rate than more traditional approaches. The study – the first trial to publish five-year results from SBRT treatment for prostate cancer – found a 98.6 percent cure rate with SBRT, a noninvasive form of radiation treatment that involves high-dose radiation beams entering the body through various angles and intersecting at the desired target. It is a state-of-the-art technology that allows for a concentrated dose to reach the tumor while limiting the radiation dose to surrounding healthy tissue. Read the article.
Feasibility for active surveillance in biopsy Gleason 3 + 4 prostate cancer: an Australian radical prostatectomy cohort.
To examine the feasibility of active surveillance for low volume Gleason sum (GS) 3 + 4 disease compared to GS 3 + 3 disease. Retrospective review of 929 patients, with biopsy proven GS 3 + 3 and 3 + 4 PCa, undergoing upfront radical prostatectomy (RP) was performed. Read the article.
Statistics Canada Study: Prostate cancer trends in Canada, 1995 to 2012
In 2012, there were 21,105 new cases of prostate cancer diagnosed, representing 23.4% of all new cancer cases among men. Overall, prostate cancer accounted for 9.5% (3,708) of all cancer deaths among men in 2012. The age-standardized incidence rate of prostate cancer has declined by an average of 3.8% per year since 2006. The annual rate of deaths due to prostate cancer has also fallen. From 1995 to 2012, the age-standardized prostate cancer mortality rate decreased by an average of 2.9% per year, a 40.9% decline over this period. Men who were diagnosed with prostate cancer in 2012 tended to …
Statistics Canada Study: Prostate cancer trends in Canada, 1995 to 2012 Read More »